Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has
been experiencing a renaissance. This success is based on progress in both preclinical and …

At the turn of the last century, the emerging field of medical oncology chose a cytotoxic
approach to cancer therapy over an immune-centered approach at a time when evidence in …

High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy
using CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex …

Cancer Immunology | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Unlike chemotherapy, which acts directly on the tumor, cancer immunotherapies exert their
effects on the immune system and demonstrate new kinetics that involve building a cellular …

Importance Response patterns with immunotherapy may differ from those of other
treatments. This warrants further investigation because some patients may benefit from …

Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-
cell activity led to development of the fully human, monoclonal antibody ipilimumab to block …

This study investigated the immunogenicity of Wilms tumor gene product 1 (WT1)–peptide
vaccination in WT1-expressing acute myeloid leukemia (AML) and myelodysplastic …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

The prognosis of patients with advanced head and neck cancer remain dismal. For this
tumor type, elevated levels of EGFR are associated with a shorter disease free survival and …